Logo image of BCRX

BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis

NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD

9.96  -0.01 (-0.1%)

After market: 9.97 +0.01 (+0.1%)

Fundamental Rating

3

Taking everything into account, BCRX scores 3 out of 10 in our fundamental rating. BCRX was compared to 557 industry peers in the Biotechnology industry. Both the profitability and financial health of BCRX have multiple concerns. BCRX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BCRX had negative earnings in the past year.
In the past year BCRX has reported a negative cash flow from operations.
BCRX had negative earnings in each of the past 5 years.
In the past 5 years BCRX always reported negative operating cash flow.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

BCRX has a better Return On Assets (-11.14%) than 83.66% of its industry peers.
BCRX's Return On Invested Capital of 7.70% is amongst the best of the industry. BCRX outperforms 93.90% of its industry peers.
Industry RankSector Rank
ROA -11.14%
ROE N/A
ROIC 7.7%
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Operating Margin of BCRX (6.59%) is better than 93.18% of its industry peers.
The Gross Margin of BCRX (96.89%) is better than 97.13% of its industry peers.
BCRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.59%
PM (TTM) N/A
GM 96.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BCRX is still creating some value.
BCRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BCRX has more shares outstanding
Compared to 1 year ago, BCRX has a worse debt to assets ratio.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.87, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
BCRX has a Altman-Z score of -1.87. This is comparable to the rest of the industry: BCRX outperforms 54.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.87
ROIC/WACC1.06
WACC7.26%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

BCRX has a Current Ratio of 2.93. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
BCRX's Current ratio of 2.93 is on the low side compared to the rest of the industry. BCRX is outperformed by 66.61% of its industry peers.
A Quick Ratio of 2.88 indicates that BCRX has no problem at all paying its short term obligations.
BCRX has a worse Quick ratio (2.88) than 65.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.88
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.45% over the past year.
BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.67%.
The Revenue has been growing by 55.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)70.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)41.67%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%56.89%

3.2 Future

The Earnings Per Share is expected to grow by 39.26% on average over the next years. This is a very strong growth
BCRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.75% yearly.
EPS Next Y107.19%
EPS Next 2Y69.99%
EPS Next 3Y58.32%
EPS Next 5Y39.26%
Revenue Next Year36.59%
Revenue Next 2Y24.38%
Revenue Next 3Y20.1%
Revenue Next 5Y15.75%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
BCRX is valuated quite expensively with a Price/Forward Earnings ratio of 26.03.
Based on the Price/Forward Earnings ratio, BCRX is valued cheaper than 91.02% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. BCRX is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 26.03
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BCRX is valued cheaper than 91.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 70.25
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 58.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.99%
EPS Next 3Y58.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (6/18/2025, 8:00:00 PM)

After market: 9.97 +0.01 (+0.1%)

9.96

-0.01 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners83.6%
Inst Owner Change5.05%
Ins Owners1.02%
Ins Owner Change18.33%
Market Cap2.08B
Analysts83.16
Price Target17.77 (78.41%)
Short Float %11.83%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.8%
Min EPS beat(2)-123.6%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)9.03%
Min EPS beat(4)-123.6%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)-1.59%
EPS beat(16)9
Avg EPS beat(16)2.12%
Revenue beat(2)1
Avg Revenue beat(2)5.78%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)12.47%
Revenue beat(4)3
Avg Revenue beat(4)5.65%
Min Revenue beat(4)-0.92%
Max Revenue beat(4)12.47%
Revenue beat(8)5
Avg Revenue beat(8)3.67%
Revenue beat(12)6
Avg Revenue beat(12)2.17%
Revenue beat(16)8
Avg Revenue beat(16)5.36%
PT rev (1m)1.46%
PT rev (3m)12.97%
EPS NQ rev (1m)151.06%
EPS NQ rev (3m)235.88%
EPS NY rev (1m)0%
EPS NY rev (3m)134.08%
Revenue NQ rev (1m)1.05%
Revenue NQ rev (3m)7.72%
Revenue NY rev (1m)1.78%
Revenue NY rev (3m)8.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.03
P/S 4.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 70.25
EPS(TTM)-0.26
EYN/A
EPS(NY)0.38
Fwd EY3.84%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS2.41
BVpS-2.16
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.14%
ROE N/A
ROCE 9.75%
ROIC 7.7%
ROICexc 58.11%
ROICexgc 58.11%
OM 6.59%
PM (TTM) N/A
GM 96.89%
FCFM N/A
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 22.77
Cap/Depr 81.2%
Cap/Sales 0.2%
Interest Coverage 0.96
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.88
Altman-Z -1.87
F-Score4
WACC7.26%
ROIC/WACC1.06
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y107.19%
EPS Next 2Y69.99%
EPS Next 3Y58.32%
EPS Next 5Y39.26%
Revenue 1Y (TTM)41.67%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%56.89%
Revenue Next Year36.59%
Revenue Next 2Y24.38%
Revenue Next 3Y20.1%
Revenue Next 5Y15.75%
EBIT growth 1Y136.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year588.75%
EBIT Next 3Y129.66%
EBIT Next 5YN/A
FCF growth 1Y79.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.35%
OCF growth 3YN/A
OCF growth 5YN/A